IDEXX Laboratories marked a 7.0% change today, compared to -1.0% for the S&P 500. Is it a good value at today's price of $516.61? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:
-
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide.
-
IDEXX Laboratories belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 30.21 and an average price to book (P/B) of 4.08
-
The company's P/B ratio is 33.08
-
IDEXX Laboratories has a trailing 12 month Price to Earnings (P/E) ratio of 52.7 based on its trailing 12 month price to earnings (EPS) of $9.8 per share
-
Its forward P/E ratio is 47.6, based on its forward earnings per share (EPS) of $10.86
-
IDXX has a Price to Earnings Growth (PEG) ratio of 2.72, which shows the company is overvalued when we factor growth into the price to earnings calculus.
-
Over the last four years, IDEXX Laboratories has averaged free cash flows of $469.45 Million, which on average grew 17.3%
-
IDXX's gross profit margins have averaged 58.0 % over the last four years and during this time they had a growth rate of 1.1 % and a coefficient of variability of 2.5 %.
-
IDEXX Laboratories has moved 22.0% over the last year compared to 15.0% for the S&P 500 -- a difference of 7.0%
-
IDXX has an average analyst rating of buy and is 0.26% away from its mean target price of $515.25 per share